This multi-receptor mechanism distinguishes retatrutide from earlier generations of incretin-based research compounds including GLP-1 mono-agonists such as semaglutide, and dual GIP/GLP-1 agonists such as tirzepatide by introducing glucagon receptor activation as an additional metabolic axis
Our medical weight loss program helps patients find the medication that best fits their individual situation, including injections, appetite suppressants, and more
Body weight and atherosclerosis Obesity is a significant risk factor for T2DM and an independent risk factor for ASCVD [45]
Data collected during the Bridge period will help policymakers assess utilization, cost-effectiveness, and clinical outcomes
Patients receive close medical supervision, goal-specific planning, and continuous motivation throughout their journey
At the same time, the drug development horizon is full of promising directions: oral formulations, multi-agonists, longer-acting molecules, and the emergence of biomarkers to personalize therapy
